SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will present data supporting its allogeneic pipeline program during the 60th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 1-4 at the San Diego Convention Center.
“ASH is the first significant medical meeting where we will present data on programs led by Allogene,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. “Our teams have spent years doing extensive preclinical research across our pipeline and the development of UCART19 with our partner Servier continues to provide insights that inform and accelerate the strategy for ALLO-501 (anti-CD19) in non-Hodgkin lymphoma. This work is important as we look ahead to our first Investigational New Drug (IND) applications for ALLO-501 and ALLO-715 (anti-BCMA) in multiple myeloma in 2019.”
The ASH abstracts are now available at www.hematology.org. The oral and poster presentations will include additional data not available in the abstracts. Details are as follows.
Allogene Oral Presentation
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies,
excluding Therapy: Development of Novel Immunotherapeutic Approaches in
Multiple Myeloma
Abstract #591
Title: ALLO-715,
an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the
Treatment of Multiple Myeloma
Presenter: Cesar Sommer,
Ph.D., Allogene Therapeutics
Session Date & Time:
Monday, December 3, 7:00-8:30 a.m. PT
Presentation Time:
7:30 a.m. PT
Location: Ballroom 20D
Allogene Poster Presentation
Session: 703. Adoptive Immunotherapy: Poster II
Abstract #3335
Title:
ALLO-819, an Allogeneic Flt3 CAR T Therapy Possessing an Off-Switch
for the Treatment of Acute Myeloid Leukemia
Presenter: Cesar
Sommer, Ph.D., Allogene Therapeutics
Session Date & Time:
Sunday, December 2, 6:00-8:00 p.m. PT
Location: Hall GH
Oral Presentation in Collaboration with Development Partner
UCART19,
sponsored by Servier1, is in Phase 1 development for the
treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).
Session: 612. Acute Lymphoblastic Leukemia: Clinical
Abstract
#896
Title: Preliminary Data on Safety, Cellular
Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19
CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with
High-Risk CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Presenter:
Reuben Benjamin, MBBS, MRCP, FRCPath, Ph.D., King’s College Hospital,
London
Session Date & Time: Monday, December 3,
4:30-6:00 p.m. PT
Presentation time: 4:45 p.m. PT
Location:
Room 6A
UCART19, ALLO-715 and ALLO-819 utilize the TALEN® gene-editing technology pioneered and owned by Cellectis.
UCART19, initially developed by Cellectis, is now exclusively licensed to Servier and is under joint clinical development between Servier and Allogene.
ALLO-715 and ALLO-819 were progressed under a joint research collaboration with Cellectis, and are directed at targets that were licensed exclusively from Cellectis. Allogene holds the exclusive global development and commercial rights for these product candidates.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.
AlloCAR T™ cell therapies are engineered from cells of healthy donors, which is intended to allow for creation of inventory for on demand use in patients. This approach is designed to eliminate the need to create personalized therapy from a patient’s own cells, simplify manufacturing, and reduce the time patients must wait for CAR T cell treatment. The Allogene portfolio includes rights to 16 pre-clinical CAR T cell therapy targets and UCART19, an AlloCAR T™ therapy candidate currently in Phase 1 sponsored by Servier for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the progress and success of the allogeneic CAR T clinical program and the timing of filing Investigational New Drug applications relating to ALLO-501 and ALLO-715. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Form S-1 originally filed with the SEC on September 14, 2018. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
1 Servier is an independent international pharmaceutical company, governed by a foundation, with Headquarters based in France
